Creating Better Medicines through Better Conjugation

Publication
Article
BioPharm InternationalBioPharm International-12-16-2013
Volume 2013 eBook
Issue 1

Clinical-stage biopharmaceutical company Ambrx leverages its site-specific bioconjugation technology through partnerships.

 

Clinical-stage biopharmaceutical company Ambrx leverages its site-specific bioconjugation technology through partnerships to bring drugs with enhanced stability and bioactivity to market.

Read this article

from BioPharm International’s 2013 Innovation Updates and Strategies eBook.

 

 

 

 

 

 

 

Recent Videos
Buy, Sell, Hold: Cell and Gene Therapy
Buy, Sell, Hold: Cell and Gene Therapy
Buy, Sell, Hold: Cell and Gene Therapy
Related Content
© 2024 MJH Life Sciences

All rights reserved.